Control of cellular events in urothelial tumours

Poster Session 23

  • Location:
    Room Stockholm (Hall B2, level 0)
  • Chairs:
     E. Compérat, Paris (FR)
     K. Junker, Homburg (DE)
     N. Malats, Madrid (ES)
  • Aims and objectives of this session

    In this session, miRNA and long coding RNA in urothelial cancer will be highlighted. Their involvement in oncogenic and tumour suppressive regulation of carcinogenesis will be presented. The session will also focus on innovative therapy applications in this malignancy.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 283
Intravesical instillation of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft

By: Inamoto T.1, Taniguchi K.2, Takahara K.1, Iwatsuki A.2, Takai T.1, Komura K.1, Yoshikawa Y.1, Uchimoto T.1, Saito K.1, Tanda N.1, Kouno J.1, Minami K.1, Uehara H.1, Hirano H.1, Nomi H.1, Kiyama S.1, Akao Y.2, Azuma H.1

Institutes: 1Osaka Medical College, Dept. of Urology, Osaka, Japan, 2Gifu University, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu, Japan

Intravesical delivery of hydrophobic drug using mucoadhesive cationic serum albumin nanoparticle as a carrier for bladder cancer therapy

By: Chiong E.1, Lu S.2, Tan C.3, Rahmat J.3, Kang E.T.2, Mahendran R.3, Neoh K.G.2

Institutes: 1National University Health System, Dept. of Urology, Singapore, Singapore, 2National University of Singapore, Dept. of Engineering, Singapore, Singapore, 3National University of Singapore, Dept. of Surgery, Singapore, Singapore

* 285
MRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors

By: Le Goux C.1, Bieche I.1, Barry De Longchamps N.2, Vacher S.1, Sibony M.3, Zerbib M.2, Damotte D.3, Pignot G.4

Institutes: 1Institut Curie, Dept. of Pharmacogénomique, Paris, France, 2Hopital Cochin, Dept. of Urology, Paris, France, 3Hopital Cochin, Dept. of Anatomopathology, Paris, France, 4Institut Paoli-Calmettes, Dept. of Urology, Marseille, France

* 286
Long noncoding RNAs in bladder cancer. Expression and quantification of MALAT1 in low and high risk tumors

By: Virseda Rogriguez A.J.1, Garcia Hernandez J.L.3, Garcia Garcia J.1, Salvatierra Perez C1, Núñez Otero J.J1, Coderque Mejia M.P.1, Hernandez Sanchez T.1, Hernandez Rivas J.M.2, Herrero Polo M.1, Martin Parada A.1, Cruz J.J.4, Gómez Veiga F.1

Institutes: 1Salamanca University Hospital, Dept. of Urology IBSAL-GITUR, Salamanca, Spain, 2Cancer Ingestigation Center of University of Salamanca, IBMCC, Salamanca, Spain, 3Resarch Unit of The University Hospital of Salamanca, Spain Center For Cancer Research (CIC-IBMCC;CSIC/USAL; IBSAL), Salamanca, Spain, 4Universitary and Hospitalary Salamanca´s Complex, Dept. of Oncology, Salamanca, Spain

Targeting protein kinase CK2 suppresses bladder cancer cell survival via glucolysis pathway

By: Tao T., Zhang X., Yang C., Cheng Y., Li P., Yang X., Deng X., Lu Q.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology And Kidney Transplantation, Nanjing, China

Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?

By: Masson-Lecomte A.1, Sirab N.2, De Reyniès A.3, Maillé P.2, Soyeux-Porte P.2, Vordos D.11, Lebret T.4, Benhamou S.5, Carrato A.6, Malats N.7, Real F.8, De La Taille A.11, Radvanyi F.9, Allory Y.10

Institutes: 1Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, 2IMRB, Translational Research In Genito-Urinary Cancers, Créteil, France, 3Ligue Nationale Contre Le Cancer, Carte D’identité des Tumeurs Program, Paris, France, 4Foch Hospital, Dept. of Urology, Suresnes, France, 5INSERM, INSERM U946, Paris, France, 6Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, 7CNIO, Genetic and Molecular Epidemiology Group, Madrid, Spain, 8CNIO, Epithelial Carcinogenesis Group, Madrid, Spain, 9CNRS, Institut Curie, UMR 144, Paris, France, 10Henri Mondor Hospital, Dept. of Pathology, Créteil, France, 11Henri Mondor Hospital, Dept. of Urology, Créteil, France

Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer

By: Hennig M.1, Jordan A.2, Chipollini J.3, Hupe M.1, Kramer M.1, Lopez L.4, Merseburger A.1, Lokeshwar V.4

Institutes: 1University of Lübeck, Dept. of Urology, Lübeck, Germany, 2Sylvester Comprehensive Cancer Center, University of Miami – Miller School of Medicine, Dept. of Urology, Miami, United States of America, 3University of Miami – Miller School of Medicine, Dept. of Urology, Miami, United States of America, 4Medical College of Georgia, Augusta University, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America

Topical and systemic immunoreaction induced by intravesical instillation of chemotherapeutic agents in a BBN-induced bladder cancer mouse model

By: Hori H., Miyake M., Tatsumi Y., Ohnishi S., Morizawa Y., Nakai Y., Anai S., Tanaka N., Fujimoto K.

Institutes: Nara Medical University, Dept. of Urology, Nara, Japan

Efficacy of recombinant bacille Calmette-Guérin secreting interleukin-15 against bladder cancer

By: Takeuchi A., Tatsugami K., Shiota M., Yokomizo A., Inokuchi J., Kashiwagi E., Takashi D., Eto M.

Institutes: Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan

Circulating tumour cells in patients with advanced urothelial carcinoma of the bladder and correlation with tumour stage, lymph node metastases and FDG-PET-findings

By: Abrahamsson J.1, Aaltonen K.2, Engilbertsson H.1, Liedberg F.1, Patschan O.1, Rydén L.2, Sjödahl G.1, Gudjonsson S.1

Institutes: 1Lund University, Dept. of Translational Medicine, Dept. of Urology, Skåne University Hospital, Malmö, Sweden, 2Lund University, Dept. of Clinical Sciences, Dept. of Oncology, Lund, Sweden

UroMark - a highly multiplex biomarker for the detection of bladder cancer

By: Feber A.1, De Winter P.2, Dhami P.3, Martinez-Fernande M4, Paul D.5, Hynes-Allen A.3, Tan W.2, Gurung P.2, Rodney S.2, Mehmood A.2, Jameson C.6, Paramio J.4, Bryan R.7, James N.7, Freeman A.6, Beck S.3, Kelly J.2

Institutes: 1Ucl Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, 2UCL Medical School, Dept. of Surgery & Interventional Science, London, United Kingdom, 3UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, 4CIEMAT, Molecular Oncology Unit, Madrid, Spain, 5UCL Cancer Insitute, Dept. of Cancer Biology, London, United Kingdom, 6University College London Hospital, Dept. of Histopathology, London, United Kingdom, 7University of Birmingham, School of Cancer Sciences, London, United Kingdom

Hormonal receptor and Her2 status correlates independently of gender with staging and grading in non muscle-invasive urothelial bladder carcinoma

By: Breyer J.1, Wirtz R.2, Denzinger S.1, Erben P.3, Burger M.1, Hartmann A.4, Otto W.1

Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology, Dept. of Pathology, Cologne, Germany, 3University of Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany